{"id":"W2123811123","doi":"10.1093/annonc/mdn370","title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"National Institute for Health and Care Research; Roche","keywords":"FOLFOX; Medicine; Oxaliplatin; Folinic acid; Internal medicine; Capecitabine; Irinotecan; Colorectal cancer; FOLFIRINOX; Neutropenia; Oncology; FOLFIRI; Population; Clinical endpoint; Fluorouracil; Surgery; Chemotherapy; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001337689,0.0006158305,0.004100292,0.0003817526,0.000242952,0.00001242636,0.0002268079,0.0002163588,0.001791222],"category_scores_gemma":[0.0006836801,0.0004828332,0.0005180115,0.0006552096,0.0005990844,0.0001687979,0.0001444221,0.0005436183,0.00002530145],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006259326,"about_ca_system_score_gemma":0.00228254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005443932,"about_ca_topic_score_gemma":0.01299669,"domain_scores_codex":[0.9954724,0.0007596433,0.001685662,0.0007386296,0.000576159,0.0007675094],"domain_scores_gemma":[0.9963973,0.001620311,0.000771168,0.0003957932,0.0005473096,0.0002681809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.89458,0.008218027,0.004272386,0.00007519769,0.005103199,0.001935288,0.02174111,0.00009025665,0.001964812,0.00007010716,0.001034173,0.06091541],"study_design_scores_gemma":[0.9059877,0.06813596,0.009970656,0.00008038848,0.0007792264,0.0001641189,0.003607664,0.00086878,0.006465717,0.0001084464,0.003279195,0.0005521089],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810724,0.006511953,0.00001061847,0.002082907,0.0007667238,0.004340535,0.0001380876,0.00007178966,0.005004937],"genre_scores_gemma":[0.9897512,0.006925115,0.0002560623,0.0006126897,0.0002684639,0.001425064,0.00008451589,0.00005099786,0.0006259396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0603633,"threshold_uncertainty_score":0.9997624,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1341549568313934,"score_gpt":0.4386820001262048,"score_spread":0.3045270432948114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}